{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:15:57Z","timestamp":1721088957909},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed multiple myeloma patients and has been the standard of care in the UK since March 2021. However, there is scant information about its impact on patients\u2019 day-to-day lives. This service evaluation aimed to qualitatively assess patients receiving lenalidomide treatment at a cancer centre in London, in order that the service might better align with needs and expectations of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted 20 semi-structured interviews among myeloma patients who were on continuous lenalidomide maintenance treatment at a specialist cancer centre in London. Members of the clinical team identified potentially eligible participants to take part, and convenience sampling was used to select 10 male and 10 female patients, median age of 58 (range, 45\u201371). The median treatment duration was 11\u00a0months (range, 1\u201360\u00a0months). Participants were qualitatively interviewed following the same semi-structured interview guide, which was designed to explore patient experience and insights of lenalidomide. Reflexive thematic analysis was used for data analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four overarching themes were as follows: (i) lenalidomide: understanding its role and rationale; (ii) reframing the loss of a treatment-free period to a return to normal life; (iii) the reality of being on lenalidomide: balancing hopes with hurdles; (iv) gratitude and grievances: exploring mixed perceptions of care and communication. Results will be used to enhance clinical services by tailoring communication to better meet patients\u2019 preferences when making treatment decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study highlights that most patients feel gratitude for being offered continuous lenalidomide and perceive it as alleviating some fears concerning relapse. It reveals variations in side effects in different age groups; younger patients reported no\/negligible side effects, whilst several older patients with comorbidities described significant symptom burden, occasionally leading to treatment discontinuation which caused distress at the perceived loss of prolonged remission. Future research should prioritise understanding the unique needs of younger patients living with multiple myeloma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08663-4","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:03:28Z","timestamp":1719907408000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma\u2014a single-centre, qualitative service evaluation study"],"prefix":"10.1007","volume":"32","author":[{"given":"Caroline","family":"Buck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Brenes Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bettio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Land","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orla","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Tarling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chara","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashu","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Sive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"2","key":"8663_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O (2018) Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol 101(2):237\u2013244. https:\/\/doi.org\/10.1111\/ejh.13083","journal-title":"Eur J Haematol"},{"issue":"1","key":"8663_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"8663_CR3","unstructured":"Gasparetto C,\u00a0Sivaraj D (2017) Understanding multiple myeloma. Jones & Bartlett Learning"},{"key":"8663_CR4","unstructured":"National Institute for Health and Care Excellence (2016) Overview: myeloma: diagnosis and management: guidance. NICE. (n.d.-c).  https:\/\/www.nice.org.uk\/guidance\/ng35. Accessed 5 Oct 2023"},{"issue":"5","key":"8663_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 46(5):671\u2013680. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.11.003","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"8663_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","volume":"12","author":"S Seitzler","year":"2019","unstructured":"Seitzler S, Finley-Oliver E, Simonelli C, Baz R (2019) Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol 12(6):419\u2013424. https:\/\/doi.org\/10.1080\/17474086.2019.1613886","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"8663_CR7","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/jan.12430","volume":"70","author":"M Stephens","year":"2014","unstructured":"Stephens M, McKenzie H, Jordens CFC (2014) The work of living with a rare cancer: multiple myeloma. J Adv Nurs 70(12):2800\u20132809. https:\/\/doi.org\/10.1111\/jan.12430","journal-title":"J Adv Nurs"},{"issue":"2","key":"8663_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252\u2013264. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"issue":"7","key":"8663_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79(7):867\u2013874. https:\/\/doi.org\/10.4065\/79.7.867","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"8663_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2354.2010.01234.x","volume":"20","author":"K Maher","year":"2011","unstructured":"Maher K, De Vries K (2011) An exploration of the lived experiences of individuals with relapsed multiple myeloma. Eur J Cancer Care 20(2):267\u2013275","journal-title":"Eur J Cancer Care"},{"key":"8663_CR11","doi-asserted-by":"crossref","unstructured":"Hauksd\u00f3ttir B (2017) Patients\u2019 experiences with multiple myeloma: a meta-aggregation of qualitative studies. Number 2\/March 2017 44(2):64-81","DOI":"10.1188\/17.ONF.E64-E81"},{"key":"8663_CR12","doi-asserted-by":"publisher","unstructured":"Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer 16(1). https:\/\/doi.org\/10.1186\/s12885-016-2410-2","DOI":"10.1186\/s12885-016-2410-2"},{"issue":"10","key":"8663_CR13","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/pon.3284","volume":"22","author":"J Lamers","year":"2013","unstructured":"Lamers J, Hartmann M, Goldschmidt H, Brechtel A, Hillengass J, Herzog W (2013) Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what? Psychooncology 22(10):2313\u20132320. https:\/\/doi.org\/10.1002\/pon.3284","journal-title":"Psychooncology"},{"issue":"8","key":"8663_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","volume":"24","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS (2018) Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 24(8):1546\u20131553. https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"8663_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, McManus S, Buzaglo JS (2020) Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Nat Compr Cancer Netw\u202f: JNCCN 18(8):1087\u20131095. https:\/\/doi.org\/10.6004\/jnccn.2020.7561","journal-title":"J Nat Compr Cancer Netw : JNCCN"},{"issue":"4","key":"8663_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365\u2013382. https:\/\/doi.org\/10.1111\/joim.12590","journal-title":"J Intern Med"},{"issue":"5","key":"8663_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/14737140.2022.2069564","volume":"22","author":"RK Gupta","year":"2022","unstructured":"Gupta RK, Gupta A, Hillengass J, Holstein SA, Suman VJ, Taneja A, McCarthy PL (2022) A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. Expert Rev Anticancer Ther 22(5):457\u2013469. https:\/\/doi.org\/10.1080\/14737140.2022.2069564","journal-title":"Expert Rev Anticancer Ther"},{"key":"8663_CR18","unstructured":"National Institute for Health and Care Excellence (2021) Overview: lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma: Guidance. NICE. (n.d.-b). https:\/\/www.nice.org.uk\/guidance\/ta680. Accessed 5 Oct 2023"},{"issue":"29","key":"8663_CR19","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Attal M (2017) lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279","journal-title":"J Clin Oncol"},{"issue":"19","key":"8663_CR20","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Harousseau JL (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England J Med 366(19):1782\u20131791","journal-title":"New England J Med"},{"key":"8663_CR21","doi-asserted-by":"crossref","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, ... & Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. New England J Med 366(19):1770\u20131781","DOI":"10.1056\/NEJMoa1114083"},{"key":"8663_CR22","doi-asserted-by":"crossref","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, ... & Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. New England J Med 371(10):895\u2013905","DOI":"10.1056\/NEJMoa1402888"},{"key":"8663_CR23","doi-asserted-by":"crossref","unstructured":"Jackson G H, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, ... & Morgan GJ (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(1):57\u201373","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"8663_CR24","doi-asserted-by":"crossref","unstructured":"Abonour R, Wagner L, Durie BG, Jagannath S, Narang M, Terebelo HR, ... & Rifkin RM (2018) Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry.\u00a0Ann Hematol\u00a097:2425\u20132436.","DOI":"10.1007\/s00277-018-3446-y"},{"issue":"15_suppl","key":"8663_CR25","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1200\/jco.2015.33.15_suppl.8523","volume":"33","author":"SA Holstein","year":"2015","unstructured":"Holstein SA, Owzar K, Richardson PG, Jiang C, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Devine SM, Hars V, Postiglione JR, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Martin TG, Shea TC, Anderson KC, McCarthy PL (2015) Updated analysis of CALGB\/ECOG\/BMT CTN 100104: Lenalidomide (LEN) vs. Placebo (PBO) maintenance therapy after Single Autologous Stem Cell Transplant (ASCT) for multiple myeloma (mm). J Clin Oncol 33(15_suppl):8523\u20138523. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.8523","journal-title":"J Clin Oncol"},{"issue":"2","key":"8663_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00520-012-1548-y","volume":"21","author":"S Acaster","year":"2012","unstructured":"Acaster S, Gaugris S, Velikova G, Yong K, Lloyd AJ (2012) Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer 21(2):599\u2013607. https:\/\/doi.org\/10.1007\/s00520-012-1548-y","journal-title":"Support Care Cancer"},{"key":"8663_CR27","doi-asserted-by":"crossref","unstructured":"M\u00fchlbacher AC, Lincke HJ, N\u00fcbling M (2008) Evaluating patients\u2019 preferences for multiple myeloma therapy, a Discrete-Choice-Experiment.\u00a0GMS Psycho-Social Medicine 5","DOI":"10.1016\/S1098-3015(10)70408-3"},{"key":"8663_CR28","doi-asserted-by":"publisher","unstructured":"Camilleri M, Bekris G, Sidhu G, Buck C, Elsden E, McCourt O, Horder J, Newrick F, Lecat C, Sive J, Papanikolaou X, Popat R, Lee L, Xu K, Kyriakou C, Rabin N, Yong K, & Fisher A (2022) The impact of Covid-19 on autologous stem cell transplantation in multiple myeloma a single-centre service evaluation. https:\/\/doi.org\/10.21203\/rs.3.rs-1446612\/v1","DOI":"10.21203\/rs.3.rs-1446612\/v1"},{"issue":"24","key":"8663_CR29","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1002\/cncr.28340","volume":"119","author":"BL Burnette","year":"2013","unstructured":"Burnette BL, Dispenzieri A, Kumar S, Harris AM, Sloan JA, Tilburt JC, Kyle RA, Rajkumar SV (2013) Treatment trade-offs in myeloma: a survey of consecutive patients about contemporary maintenance strategies. Cancer 119(24):4308\u20134315. https:\/\/doi.org\/10.1002\/cncr.28340","journal-title":"Cancer"},{"issue":"29","key":"8663_CR30","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1200\/JCO.2017.74.7014","volume":"35","author":"JR Mikhael","year":"2017","unstructured":"Mikhael JR (2017) Maintenance lenalidomide after transplantation in multiple myeloma prolongs survival-in most. J Clin Oncol 35(29):3269\u20133271","journal-title":"J Clin Oncol"},{"issue":"6996","key":"8663_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.311.6996.42","volume":"311","author":"C Pope","year":"1995","unstructured":"Pope C, Mays N (1995) Qualitative research: reaching the parts other methods cannot reach: an introduction to qualitative methods in health and Health Services Research. BMJ 311(6996):42\u201345. https:\/\/doi.org\/10.1136\/bmj.311.6996.42","journal-title":"BMJ"},{"key":"8663_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/ijpvm.IJPVM_321_19","volume":"12","author":"V Renjith","year":"2021","unstructured":"Renjith V, Yesodharan R, Noronha JA, Ladd E, George A (2021) Qualitative methods in health care research. Int J Prev Med 12:20. https:\/\/doi.org\/10.4103\/ijpvm.IJPVM_321_19","journal-title":"Int J Prev Med"},{"key":"8663_CR33","unstructured":"NHS Health Research Authority (2017) Do I need NHS ethics approval? Retrieved from https:\/\/hra-decisiontools.org.uk"},{"issue":"13","key":"8663_CR34","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD (2016) Sample size in qualitative interview studies: guided by information power. Qual Health Res 26(13):1753\u20131760","journal-title":"Qual Health Res"},{"key":"8663_CR35","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V (2021) Thematic analysis: a practical guide. SAGE,\u00a0London","DOI":"10.1007\/978-3-319-69909-7_3470-2"},{"issue":"4","key":"8663_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V (2019) Reflecting on reflexive thematic analysis. Qual Res Sport, Exerc Health 11(4):589\u2013597","journal-title":"Qual Res Sport, Exerc Health"},{"key":"8663_CR37","volume-title":"A realist theory of Science","author":"R Bhaskar","year":"2015","unstructured":"Bhaskar R (2015) A realist theory of Science. Routledge"},{"key":"8663_CR38","unstructured":"Andrews T (2012) What is social constructionism?. Grounded Theory Rev 11(1)"},{"issue":"3","key":"8663_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/14780887.2020.1769238","volume":"18","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V (2021) One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual Res Psychol 18(3):328\u2013352","journal-title":"Qual Res Psychol"},{"issue":"6","key":"8663_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349\u2013357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042","journal-title":"Int J Qual Health Care"},{"key":"8663_CR41","doi-asserted-by":"crossref","unstructured":"McCourt O, Fisher A, Land J, Ramdharry G, Yong K (2023) The views and experiences of people with myeloma referred for autologous stem cell transplantation, who declined to participate in a physiotherapist-led exercise trial: a qualitative study.\u00a0Physiotherapy Theory and Practice 1\u201313","DOI":"10.1080\/09593985.2023.2244068"},{"issue":"5","key":"8663_CR42","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0000000000000425","volume":"40","author":"M Craike","year":"2017","unstructured":"Craike M, Hose K, Courneya KS, Harrison SJ, Livingston PM (2017) Physical activity preferences for people living with multiple myeloma: a qualitative study. Cancer Nurs 40(5):E1\u2013E8","journal-title":"Cancer Nurs"},{"key":"8663_CR43","doi-asserted-by":"publisher","first-page":"112552","DOI":"10.1016\/j.socscimed.2019.112552","volume":"240","author":"Y Wang","year":"2019","unstructured":"Wang Y, McKee M, Torbica A, Stuckler D (2019) Systematic literature review on the spread of health-related misinformation on social media. Soc Sci Med 240:112552","journal-title":"Soc Sci Med"},{"issue":"1","key":"8663_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/pon.1051","volume":"16","author":"MS Vos","year":"2007","unstructured":"Vos MS, de Haes JC (2007) Denial in cancer patients, an explorative review. Psychooncology 16(1):12\u201325. https:\/\/doi.org\/10.1002\/pon.1051","journal-title":"Psychooncology"},{"issue":"1","key":"8663_CR45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/07357900500449678","volume":"24","author":"T Rabinowitz","year":"2006","unstructured":"Rabinowitz T, Peirson R (2006) \u201cNothing is wrong, doctor\u201d: understanding and managing denial in patients with cancer. Cancer Investig 24(1):68\u201376. https:\/\/doi.org\/10.1080\/07357900500449678","journal-title":"Cancer Investig"},{"issue":"4","key":"8663_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s12288-021-01410-3","volume":"37","author":"VR Pydi","year":"2021","unstructured":"Pydi VR, Bala SC, Kuruva SP, Chennamaneni R, Konatam ML, Gundeti S (2021) Multiple myeloma in young adults: a single centre real world experience. Indian J Hematol Blood Transfus 37(4):679\u2013683. https:\/\/doi.org\/10.1007\/s12288-021-01410-3","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"11","key":"8663_CR47","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2020.2839","volume":"6","author":"HK Sanoff","year":"2020","unstructured":"Sanoff HK (2020) Managing grief, loss, and connection in oncology\u2014what COVID-19 has taken. JAMA Oncol 6(11):1700\u20131701","journal-title":"JAMA Oncol"},{"issue":"5","key":"8663_CR48","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jpainsymman.2020.06.003","volume":"60","author":"MS Weaver","year":"2020","unstructured":"Weaver MS, Neumann ML, Navaneethan H, Robinson JE, Hinds PS (2020) Human touch via touchscreen: rural nurses\u2019 experiential perspectives on telehealth use in pediatric hospice care. J Pain Symptom Manage 60(5):1027\u20131033","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"8663_CR49","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.25764","volume":"95","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Majhail NS (2020) Treatment and disease-related complications in multiple myeloma: implications for survivorship. Am J Hematol 95(6):672\u2013690","journal-title":"Am J Hematol"},{"issue":"2","key":"8663_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1188\/21.ONF.151-160","volume":"48","author":"MR LeBlanc","year":"2021","unstructured":"LeBlanc MR, LeBlanc TW, Leak Bryant A, Pollak KI, Bailey DE, Smith SK (2021) A qualitative study of the experiences of living with multiple myeloma. Oncol Nurs Forum 48(2):151\u2013160. https:\/\/doi.org\/10.1188\/21.ONF.151-160","journal-title":"Oncol Nurs Forum"},{"issue":"6","key":"8663_CR51","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","volume":"29","author":"MR LeBlanc","year":"2020","unstructured":"LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK (2020) How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review. Qual Life Res 29(6):1419\u20131431. https:\/\/doi.org\/10.1007\/s11136-019-02392-6","journal-title":"Qual Life Res"},{"issue":"12","key":"8663_CR52","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3109\/10428194.2016.1170828","volume":"57","author":"LJ Costa","year":"2016","unstructured":"Costa LJ, Hari PN, Kumar SK (2016) Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma 57(12):2827\u20132832. https:\/\/doi.org\/10.3109\/10428194.2016.1170828","journal-title":"Leuk Lymphoma"},{"key":"8663_CR53","doi-asserted-by":"crossref","unstructured":"Kitson A, Harvey G (2015) Facilitating an evidence-based innovation into practice.\u00a0Implementing Evidence-Based Practice in Healthcare: A Facilitation Guide","DOI":"10.4324\/9780203557334"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08663-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08663-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08663-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T09:21:33Z","timestamp":1721035293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08663-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["8663"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08663-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}